Advertisement

Adaptive Designs for Clinical Trials with Highly Successful Treatments

  • Anastasia Ivanova
  • William F. Rosenberger
Article

Abstract

We compare the performance of two adaptive designs and equal allocation in a clinical trial with two highly successful treatments and binary outcomes. The measure of interest in the trial is the odds ratio. The goal of the adaptive design is to decrease the total number of failures compared to equal allocation while keeping the power at the same level. One design is based on sequential maximum likelihood estimation, the other on an urn model. We find that the urn model produces a better procedure than the sequential maximum likelihood approach and equal allocation, in that it yields fewer expected treatment failures, maintains the power of the asymptotic test, and is more powerful when the Fisher’s exact test is used. We conclude that adaptive designs have attractive properties when both treatments are highly successful.

Key Words

Ethics Measures of association Optimal allocation Power Urn models 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. Boston, MA: Wright PSG; 1981, 41.Google Scholar
  2. 2.
    Melfi V, Page C. Variability in adaptive designs for estimation of success probabilities. In New Developments and Applications in Experimental Design. Flournoy N, Rosenberger WF, Wong WK, eds. Hay-ward, CA: Institute of Mathematical Statistics: 1998, 106–114.CrossRefGoogle Scholar
  3. 3.
    Ivanova AV, Rosenberger WF. A comparison of urn designs for randomized clinical trials of K > 2 treatments. J Biopharm Stat. 2000;10:93–107.CrossRefGoogle Scholar
  4. 4.
    Rosenberger WF, Stallard N, Inanova A, Harper C, Ricks M. Optimal adaptive designs for binary response trials. Biometrics. 2001;57:833–837.CrossRefGoogle Scholar
  5. 5.
    Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Boca Raton, FL: Chapman and Hall/CRC; 2000, 329.Google Scholar
  6. 6.
    The COMPASS Investigators. Randomized double-blind study comparing saruplase with streptokinase in acute myocardial infarction: the COMPASS equivalence trial. J Am Coll Cardiol. 1998;31:487–493.CrossRefGoogle Scholar
  7. 7.
    Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, Jiminez E, O’Neil E, Bazin B, Del-fraissy J, Culnane M, Coombs R, Elkins M, Moye J, Stratton P, Balsley J for the Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. New Engl J Med. 1994;331:1173–1180.CrossRefGoogle Scholar
  8. 8.
    Rosenberger WF, Seshaiyer P. Adaptive survival trials. J Biopharm Stat. 1997;7:617–624.CrossRefGoogle Scholar
  9. 9.
    Rosenberger WF. Randomized play-the-winner clinical trials: review and recommendations. Control Clin Trials. 1999;20:328–335.CrossRefGoogle Scholar
  10. 10.
    Wei LJ, Durham S. The randomized play-the-winner rule in medical trials. J Am Stat Assoc. 1978;73: 840–843.CrossRefGoogle Scholar
  11. 11.
    Ivanova AV, Rosenberger WF, Durham SD, Flournoy N. A birth and death urn for randomized clinical trials: asymptotic results. Sankhya B. 2000;62:104–118.Google Scholar

Copyright information

© Drug Information Association, Inc 2001

Authors and Affiliations

  • Anastasia Ivanova
    • 1
  • William F. Rosenberger
    • 2
  1. 1.Department of BiostatisticsUniversity of North Carolina at Chapel HillChapel HillUSA
  2. 2.University of Maryland, Baltimore County and BaltimoreBaltimoreUSA

Personalised recommendations